TY - JOUR T1 - Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer: First Report of the HYPER-O Registry JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 61-69 LP - 61-69 DO - 10.1111/IGC.0b013e3181c50cde VL - 20 IS - 1 AU - Cyril William Helm AU - Scott D. Richard AU - Jianmin Pan AU - David Bartlett AU - Martin D. Goodman AU - Rick Hoefer AU - Sam S. Lentz AU - Edward A. Levine AU - Brian W. Loggie AU - Daniel S. Metzinger AU - Brigitte Miller AU - Lynn Parker AU - James E. Spellman AU - Paul H. Sugarbaker AU - Robert P. Edwards AU - Shesh N. Rai Y1 - 2010/01/01 UR - http://ijgc.bmj.com/content/20/1/61-69.abstract N2 - Introduction: An analysis of experience of surgical and gynecologic oncologists in the United States with the use of hyperthermic intraperitoneal chemotherapy for women with invasive epithelial ovarian cancer (EOC).Methods: An Internet-based registry (HYPER-O) collected data from collaborating institutions. Eligibility included women with EOC treated with hyperthermic intraperitoneal chemotherapy. Borderline and nonepithelial cancers were excluded.Results: As of July 1, 2008, 141 women were eligible for analysis treated at the following time points: frontline (n = 26), interval debulking (n = 19), consolidation (n = 12), and recurrence (n = 83). The mean perfusion temperatures were 38.5 to 43.6°C (median, 41.9°C) for inflow and 36.9 to 42.9°C (median, 41°C) for outflow for 30 to 120 minutes. Treatment was with a platinum agent (n = 72), mitomycin (n = 53), or a combination (n = 14). Median follow-up was 18 months (range, 0.3-140.5 months) and median overall survival 30.3 months (95% confidence interval, 23.0-37.6) with 2-, 5-, and 10-year overall survival probabilities of 49.1%, 25.4%, and 14.3%, respectively. Of the 141 patients, 110 (78%) experienced recurrence of ovarian cancer and 87 died, 3 (0.5%) dying within 30 days of surgery. In the multivariable analysis, the factors significant for increased survival were sensitivity to platinum response (P = 0.048), completeness of cytoreduction scores of 1 or 0 (P = 0.025), carboplatin alone or a combination of 2 or more chemotherapy agents used (P = 0.011), and duration of hospital stays of 10 days or less (P = 0.021).Conclusions: Hyperthermic intraperitoneal chemotherapy is a viable additional treatment option for patients with invasive EOC and may extend life in selected groups. It warrants further study in randomized controlled trials. ER -